drugset
Drugs / ADL-018
last change Aug 2025 re-read 2 minutes ago

ADL-018

also known as ADL-018 Injection
Investigated by
Kashiv BioSciences, LLC

Trials 1 · a red edge is where a trial was stopped

today NCT05413161 · Ph 1
2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05413161 Jul 2022 → Feb 2023 — Kashiv BioSciences, LLC Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06929052 Comparator Jan → Aug 2025 — Kashiv BioSciences, LLC Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as ADL-018 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05413161 ↗
1

NCT06929052 ↗
Known as ADL-018 Injection “Reference Product (B): ADL-018 Injection 150mg/mL solution in a single dose pre-filled syringe manufactured/supplied by Kashiv BioSciences LLC, USA” NCT06929052 ↗
Route Subcutaneous “following single subcutaneous dose” NCT05413161 ↗